UT Health Rapamycin Study: Three Sub-Studies, Two Timelines, and No Results Yet

UT Health San Antonio announced a National Institute on Aging-funded rapamycin research program in March 2026. The announcement is important because it focuses on dose, schedule, safety, and biological response in humans. It is not evidence that rapamycin extends human life, and it does not establish a clinic prescribing protocol.

The original version of this article combined two different descriptions on the university page. One is a multi-phase project whose third sub-study plans to randomize about 84 older adults to daily rapamycin, intermittent rapamycin, or placebo. The other is a currently advertised six-week study of rapamycin and everolimus with four weeks of follow-up.¹

Those timelines and participant groups must not be treated as one trial.

Review note, August 28, 2026: WLC rebuilt this article from the UT Health San Antonio announcement. We removed animal lifespan percentages, speculative clinic dosing, projected result dates, and claims that the study had already produced prescribing guidance. The university release does not provide a trial registry identifier, so WLC does not guess one.

What UT Health San Antonio announced

The university describes a project with three linked sub-studies:¹

1. A study in younger adults examining immune and metabolic markers.
2. A study in older adults comparing dosing schedules to identify a dose that reaches biological targets while limiting side effects.
3. A randomized, placebo-controlled study of approximately 84 older adults comparing daily rapamycin, intermittent rapamycin, and placebo.

For the third sub-study, the announcement describes six months of treatment followed by six months of observation. Its purpose is to examine how different schedules affect measures related to aging biology and health, not to prove that the drug treats a specific disease.

The investigators also emphasize pharmacokinetics: how the body absorbs, distributes, and clears the drug. That matters because a dose schedule borrowed from transplant medicine, a small research study, or a commercial clinic may produce a different exposure profile.

The separate recruitment notice on the same page

The university page ends with a recruitment section for healthy adults aged 65 to 90. It describes a six-week study involving rapamycin and everolimus, followed by four weeks of observation. It also lists screening conditions such as independent living, non-smoking status, and no diabetes or glucose-lowering medication.¹

That recruitment notice does not match the 84-person, six-month protocol described earlier on the page. It may be one of the preliminary sub-studies, but the announcement does not explicitly map it to a numbered sub-study or provide a registry record.

The safe interpretation is narrow:

• the research program contains several stages;
• at least two study timelines are described;
• the short recruitment cohort should not be presented as the 84-person randomized study;
• eligibility for one cohort does not establish eligibility for another.

Anyone considering participation should request the exact protocol title, registry identifier, consent document, randomization details, and visit schedule from the study team.

What the study is designed to answer

The program may help answer practical questions that commercial use often skips:

Question	Why it matters
How does exposure differ by schedule?	Daily and intermittent dosing cannot be assumed to have the same effect or risk.
Which dose reaches the intended biological target?	A prescribed amount is not useful if target engagement is unknown.
Which adverse effects appear at each exposure?	Safety depends on dose, schedule, participant health, and monitoring.
Do immune and metabolic markers change?	These signals can support later trials, but are not clinical proof on their own.
Do changes persist after treatment stops?	A short-lived biomarker shift may have limited clinical meaning.

This is the value of a staged research design. It can reduce uncertainty before a much larger trial attempts to measure functional or disease outcomes.

What it does not answer yet

The announcement reports a study launch, not results. It does not show that rapamycin:

• extends human lifespan;
• prevents dementia, cardiovascular disease, cancer, or frailty;
• improves strength, cognition, mobility, or quality of life;
• has a validated anti-aging dose for healthy adults;
• is safer when taken weekly rather than daily;
• should be prescribed by longevity clinics outside a trial.

Animal studies and mechanistic research helped motivate human trials. They cannot supply the missing human outcome data. Percentages from mice, flies, or yeast are especially misleading when placed next to a human study announcement without species, protocol, and endpoint context.

Why dose cannot be copied from a clinic menu

Rapamycin prescribing in longevity settings varies widely. A clinic may describe a weekly, intermittent, or cycling protocol, but frequency alone does not reveal total exposure, blood concentration, interaction risk, or target engagement.

The UT project is investigating these variables rather than assuming the answer. That is a reason to wait for protocol-specific results, not a reason to treat the launch as validation of an existing commercial regimen.

A credible discussion should distinguish:

• dose: the amount taken at one time;
• schedule: how often the dose is taken;
• exposure: the concentration reached over time;
• target engagement: whether the intended biological pathway changes;
• clinical outcome: whether participants function better or experience less disease;
• safety outcome: what adverse effects, laboratory changes, infections, or discontinuations occur.

Moving one item in this chain does not prove the next.

Questions for the research team

Prospective participants should obtain answers in writing:

1. Which of the three sub-studies is currently recruiting?
2. What is the exact trial registry identifier?
3. Is the intervention rapamycin, everolimus, or both?
4. What are the treatment and follow-up periods for this specific cohort?
5. Is allocation randomized and is there a placebo group?
6. Which primary outcome was registered before recruitment?
7. Which laboratory values, infections, symptoms, and drug interactions are monitored?
8. What circumstances require a dose change or withdrawal?
9. Will participants receive individual results, and which results are research-only?
10. Who provides medical care if an adverse event occurs after a study visit?

These questions are normal trial due diligence. They are more useful than asking whether rapamycin is a longevity drug in the abstract.

Questions for a commercial clinic

If a clinic cites the UT announcement to support off-trial prescribing, ask:

1. Which completed human trial supports its exact dose and schedule?
2. Is the clinic reproducing a registered protocol or creating its own?
3. Which outcome is expected to improve, and over what period?
4. What evidence links that outcome to better health rather than a biomarker change?
5. How are medication interactions and infection risk reviewed?
6. Which baseline and follow-up tests are included in the quoted price?
7. What stop rules are used?
8. Are adverse events tracked and published, including people who discontinue?

The phrase “clinically studied” is insufficient if the cited study is still recruiting or tests a different regimen.

How this fits with other 2026 healthspan trials

The UT program is one part of a broader shift toward testing interventions with defined protocols and measurable outcomes. The ARPA-H PROSPR program is also pursuing healthspan trial infrastructure, but funding announcements and study designs are not results.

For buyers, the useful distinction is between:

• a hypothesis supported by mechanisms or animal work;
• a registered human protocol;
• a completed trial with biomarker results;
• replicated evidence for functional or disease outcomes;
• a treatment guideline.

Rapamycin for healthy longevity has not completed that ladder.

Bottom line

UT Health San Antonio has launched a meaningful research program into rapamycin dose, schedule, biological response, and safety. The public announcement describes three sub-studies and a separate short recruitment protocol, but it provides no outcome data and no registry identifier that WLC can verify from the release.

Do not translate the launch into a clinic dose, a result date, or proof of longer life. The next useful evidence will be a clearly registered protocol, prespecified outcomes, adverse-event reporting, and completed human results.

Footnotes

1. UT Health San Antonio. Large rapamycin clinical trial launches at UT Health San Antonio. March 16, 2026. ↩ ↩² ↩³